| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 12/07/2022 | 322.54% | Ladenburg Thalmann | → $6 | Initiates Coverage On | → Buy |
| 02/01/2021 | 1026.76% | HC Wainwright & Co. | $20 → $16 | Maintains | Buy |
| 06/15/2020 | 1308.45% | HC Wainwright & Co. | → $20 | Initiates Coverage On | → Buy |
What is the target price for NeuroBo Pharmaceuticals (NRBO)?
The latest price target for NeuroBo Pharmaceuticals (NASDAQ: NRBO) was reported by Ladenburg Thalmann on December 7, 2022. The analyst firm set a price target for $6.00 expecting NRBO to rise to within 12 months (a possible 322.54% upside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for NeuroBo Pharmaceuticals (NRBO)?
The latest analyst rating for NeuroBo Pharmaceuticals (NASDAQ: NRBO) was provided by Ladenburg Thalmann, and NeuroBo Pharmaceuticals initiated their buy rating.
When is the next analyst rating going to be posted or updated for NeuroBo Pharmaceuticals (NRBO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NeuroBo Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NeuroBo Pharmaceuticals was filed on December 7, 2022 so you should expect the next rating to be made available sometime around December 7, 2023.
Is the Analyst Rating NeuroBo Pharmaceuticals (NRBO) correct?
While ratings are subjective and will change, the latest NeuroBo Pharmaceuticals (NRBO) rating was a initiated with a price target of $0.00 to $6.00. The current price NeuroBo Pharmaceuticals (NRBO) is trading at is $1.42, which is within the analyst's predicted range.